TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $23.31 which represents a slight increase of $0.06 or 0.26% from the prior close of $23.25. The stock opened at $23 ...

TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

TG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

As global markets react to the Federal Reserve's first rate cut in over four years, U.S. stocks have surged to new highs, with small-cap indexes showing notable resilience despite remaining below ...

During the last three months, 4 analysts shared their evaluations of TG Therapeutics TGTX, revealing diverse outlooks from ...

TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $23.19 which represents a slight increase of $0.12 or 0.52% from the prior close of $23.07. The stock opened at $22 ...

Short TGTX slightly under 26.13, target 22.17, stop loss @ 26.21 Check the time stamp on this data. Updated AI-Generated ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Boston Scientific (BSX – Research Report) with bullish ...

TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...